Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, Sirnaomics has established a drug candidate pipeline.

The company's lead candidate is STP122G, which represents the first drug candidate, which is in Phase I development as of Q1 2024.